Cite
Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial.
MLA
Yaeko Kondo, et al. “Sitagliptin Monotherapy Has Better Effect on Insulinogenic Index than Glimepiride Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: A 52-Week, Multicenter, Parallel-Group Randomized Controlled Trial.” Diabetology & Metabolic Syndrome, vol. 8, Feb. 2016, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s13098-016-0131-y.
APA
Yaeko Kondo, Norio Harada, Akihiro Hamasaki, Shizuka Kaneko, Koichiro Yasuda, Eiichi Ogawa, Shin-ichi Harashima, Hiroko Yoneda, Yoshihito Fujita, Norikazu Kitano, Yoshio Nakamura, Fujio Matsuo, Megumi Shinji, Shiro Hinotsu, Takeo Nakayama, & Nobuya Inagaki. (2016). Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial. Diabetology & Metabolic Syndrome, 8, 1–9. https://doi.org/10.1186/s13098-016-0131-y
Chicago
Yaeko Kondo, Norio Harada, Akihiro Hamasaki, Shizuka Kaneko, Koichiro Yasuda, Eiichi Ogawa, Shin-ichi Harashima, et al. 2016. “Sitagliptin Monotherapy Has Better Effect on Insulinogenic Index than Glimepiride Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: A 52-Week, Multicenter, Parallel-Group Randomized Controlled Trial.” Diabetology & Metabolic Syndrome 8 (February): 1–9. doi:10.1186/s13098-016-0131-y.